RU 486 prevents the acute effects of cortisol on glucose and leucine metabolism

• Published in: The journal of clinical endocrinology and metabolism Vol. 80; no. 2; p. 379
• Main Authors: Garrel, D R, Moussali, R, De Oliveira, A, Lesiège, D, Larivière, F
• Format: Journal Article
• Language: English
• Published: United States 01-02-1995
• Subjects: Adrenocorticotropic Hormone - blood; Adult; Blood Glucose - metabolism; Double-Blind Method; Glucose - metabolism; Hormones - blood; Humans; Hydrocortisone - blood; Hydrocortisone - pharmacology; Kinetics; Leucine - metabolism; Male; Mifepristone - pharmacology; Oxidation-Reduction; Pulmonary Gas Exchange - drug effects; Time Factors; Americas; Adrenal Cortex Hormones; Nutrition Disorders; Carbohydrate Metabolic Effects; Biology; Hormones; North America; Endocrine System; Diseases; Proteins; Studies; Canada; Northern America; Developed Countries; Double-blind Studies; Deficiency Diseases; Glucose Metabolism Effects; Research Report; Physiology; Hormone Antagonists; Ru-486; Metabolic Effects
• ISSN: 0021-972X
• DOI: 10.1210/jc.80.2.379

Glucocorticoids have deleterious effects on glucose and protein metabolism. RU 486 is an antiprogestin with antiglucocorticoid activity, which could be used to prevent the undesirable metabolic effects of glucocorticoids. A randomized, controlled, double blind study was performed in eight healthy male volunteers who were tested four times: during the iv infusion of cortisol (2 micrograms/kg.min for 5 h) after the oral ingestion of RU 486 (600 mg) or a placebo, and during the infusion of a normal saline solution with placebo or RU 486 ingestion. During each test, a primed continuous iv infusion of D-[6,6-2H]glucose and [1-13C-]leucine was given for the calculation of hepatic glucose production and plasma leucine appearance rate. 13CO2 enrichment in breath was measured for the calculation of leucine oxidation. Plasma concentrations of cortisol, ACTH, insulin, C-peptide, glucagon, and GH were measured at regular intervals. Compared to saline, cortisol infusion increased plasma glucose 5.5 +/- 0.6 vs. 4.7 +/- 0.4 mmol/L; P < 0.01) and leucine (179 +/- 35 vs. 155 +/- 35 mumol/L; P < 0.01) concentrations as well as the leucine appearance rate (2.24 +/- 0.3 vs. 2.0 +/- 0.28 mumol/kg.min; P < 0.05) and oxidation (0.51 +/- 0.22 vs. 0.39 +/- 0.06 mumol/kg.min; P < 0.01), and there was no change in hepatic glucose production. None of the metabolic changes induced by cortisol were seen when cortisol was administered after the ingestion of RU 486. When RU 486 was given before normal saline infusion, plasma glucose concentrations were transiently lower than those after placebo ingestion, as was the hepatic glucose production. No change in insulin, C-peptide, or glucagon was seen between tests. GH concentrations were higher during cortisol infusion, but not when cortisol was administered after the ingestion of RU 486. The following conclusions were reached. 1) RU 486 can suppress the effects of acute hypercortisolemia on glucose and protein metabolism and GH secretion in man. Long term studies are warranted to explore the potential of antiglucocorticoid molecules as preventive agents of the deleterious effects of chronic glucocorticoid administration. 2) RU 486 is useful molecule for studying the metabolic effects of cortisol in man.